Timing of Surgical Intervention in Buruli Ulcer Patients Treated With Antibiotics (Burulitime)
Timing of the Decision on Surgical Intervention for Buruli Ulcer Patients Treated With Rifampicin/Streptomycin
Sponsor: Laboratoire de Référence des Mycobactéries
Listed as NCT01432925, this NA trial focuses on Buruli Ulcer and Mycobacterium Ulcerans Disease and remains completed. Sponsored by Laboratoire de Référence des Mycobactéries, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Aug 2019 — Jan 2021 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jun 2018 — Aug 2019 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Laboratoire de Référence des Mycobactéries
- PNLUB, Ministère de la santé, Cotonou, République du Bénin.
- University Medical Center Groningen
For direct contact, visit the study record on ClinicalTrials.gov .